Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8+ T cell response: A comparative study

Journal of Controlled Release

Volumn 192, Issue , 2014, Pages 209-218

  Cruz, Luis J ^a   Rosalia, Rodney A ^a   Kleinovink, Jan Willem ^a   Rueda, Felix ^b   Löwik, Clemens W G M ^a   Ossendorp, Ferry ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Dendritic cells; Immunotherapy; Molecular imaging; Nanoparticles; PLGA; Targeting

Indexed keywords

CELLS; COPOLYMERS; CYTOLOGY; MOLECULAR IMAGING; MOLECULES; MONOCLONAL ANTIBODIES; NANOPARTICLES; SILVER; VACCINES;

COMPARATIVE STUDIES; DENDRITIC CELLS; IMMUNOTHERAPY; MONOCLONAL ANTIBODIES (MABS); PLGA; POLY(LACTIC-CO-GLYCOLIC ACID); TARGETING; TOLL-LIKE RECEPTORS; T-CELL RESPONSE;

T-CELLS; MOLECULAR IMAGING;

CD40 ANTIGEN; DEC 205 ANTIGEN; GLYCOPROTEIN P 15095; INTERLEUKIN 12; NANOPARTICLE; OVALBUMIN; POLYGLACTIN; T LYMPHOCYTE ANTIGEN; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; DEC-205 RECEPTOR; LACTIC ACID; LECTIN; LEUKOCYTE ANTIGEN; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; CANCER VACCINE; DEC 205 PROTEIN; GAMMA INTERFERON; LECTIN RECEPTOR; MONOCLONAL ANTIBODY; POLY(LACTIC CO GLYCOLIC ACID)NANOPARTICLE; POLY(LACTIC CO GLYCOLIC ACID)NANOPARTICLE CD11C PROTEIN VACCINE; POLY(LACTIC CO GLYCOLIC ACID)NANOPARTICLE CD40 PROTEIN VACCINE; POLY(LACTIC CO GLYCOLIC ACID)NANOPARTICLE DEC 205 PROTEIN VACCINE; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7;

ANIMAL EXPERIMENT; ARTICLE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TARGET CELL; TRANSMISSION ELECTRON MICROSCOPY; VACCINATION; ZETA POTENTIAL; ANIMAL; C57BL MOUSE; CHEMISTRY; DRUG DELIVERY SYSTEM; IMMUNOLOGY; ULTRASTRUCTURE; ANIMAL CELL; CELL ACTIVATION; CELL SPECIFICITY; CELL SURFACE; CYTOKINE PRODUCTION; CYTOLYSIS; INTERNALIZATION;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD11C; ANTIGENS, CD40; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; DRUG DELIVERY SYSTEMS; LACTIC ACID; LECTINS, C-TYPE; MICE, INBRED C57BL; NANOPARTICLES; OVALBUMIN; POLYGLYCOLIC ACID; RECEPTORS, CELL SURFACE;

EID: 84907246984     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.07.040     Document Type: Article

References (35)

1. G.P. Dunn, A.T. Bruce, H. Ikeda, L.J. Old, and R.D. Schreiber Cancer immunoediting: from immunosurveillance to tumor escape Nat. Immunol. 3 2002 991 998 (Pubitemid 35363648)
2. J.B. Swann, and M.J. Smyth Immune surveillance of tumors J. Clin. Invest. 117 2007 1137 1146 (Pubitemid 46718398)
3. R. Kim, M. Emi, and K. Tanabe Cancer immunoediting from immune surveillance to immune escape Immunology 121 2007 1 14 (Pubitemid 46537674)
4. C.L. Hutchings, S.C. Gilbert, A.V. Hill, and A.C. Moore Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity J. Immunol. 175 2005 599 606 (Pubitemid 40884366)
5. A. Paschen, S. Eichmuller, and D. Schadendorf Identification of tumor antigens and T-cell epitopes, and its clinical application Cancer Immunol. Immunother. CII 53 2004 196 203 (Pubitemid 38328042)
6. G.C. Spagnoli, M. Adamina, M. Bolli, W.P. Weber, P. Zajac, W. Marti, D. Oertli, M. Heberer, and F. Harder Active antigen-specific immunotherapy of melanoma: from basic science to clinical investigation World J. Surg. 29 2005 692 699 (Pubitemid 41187527)
7. J. Banchereau, F. Briere, C. Caux, J. Davoust, S. Lebecque, Y.J. Liu, B. Pulendran, and K. Palucka Immunobiology of dendritic cells Annu. Rev. Immunol. 18 2000 767 811 (Pubitemid 30365397)
8. C.M. Celluzzi, J.I. Mayordomo, W.J. Storkus, M.T. Lotze, and L.D. Falo Jr. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity J. Exp. Med. 183 1996 283 287 (Pubitemid 26028768)
9. R.M. Steinman The dendritic cell system and its role in immunogenicity Annu. Rev. Immunol. 9 1991 271 296
10. L. Delamarre, and I. Mellman Harnessing dendritic cells for immunotherapy Semin. Immunol. 23 2011 2 11
11. J.M. Blander, and R. Medzhitov Toll-dependent selection of microbial antigens for presentation by dendritic cells Nature 440 2006 808 812
12. E. Schlosser, M. Mueller, S. Fischer, S. Basta, D.H. Busch, B. Gander, and M. Groettrup TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses Vaccine 26 2008 1626 1637
13. U. Wille-Reece, B.J. Flynn, K. Lore, R.A. Koup, R.M. Kedl, J.J. Mattapallil, W.R. Weiss, M. Roederer, and R.A. Seder HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8 + T cell responses in nonhuman primates Proc. Natl. Acad. Sci. U. S. A. 102 2005 15190 15194 (Pubitemid 41513357)
14. P.J. Tacken, I.J. de Vries, R. Torensma, and C.G. Figdor Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting Nat. Rev. Immunol. 7 2007 790 802 (Pubitemid 47480309)
15. A. Rolink, F. Melchers, and J. Andersson The SCID but not the RAG-2 gene product is required for S mu-S epsilon heavy chain class switching Immunity 5 1996 319 330 (Pubitemid 26366755)
16. L.J. Cruz, P.J. Tacken, F. Rueda, J.C. Domingo, F. Albericio, and C.G. Figdor Targeting nanoparticles to dendritic cells for immunotherapy Methods Enzymol. 509 2012 143 163
17. L.J. Cruz, P.J. Tacken, F. Bonetto, S.I. Buschow, H.J. Croes, M. Wijers, I.J. de Vries, and C.G. Figdor Multimodal imaging of nanovaccine carriers targeted to human dendritic cells Mol. Pharm. 8 2011 520 531
18. D.H. Schuurhuis, A. Ioan-Facsinay, B. Nagelkerken, J.J. van Schip, C. Sedlik, C.J. Melief, J.S. Verbeek, and F. Ossendorp Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8 + CTL responses in vivo J. Immunol. 168 2002 2240 2246 (Pubitemid 34171824)
19. R.A. Rosalia, E.D. Quakkelaar, A. Redeker, S. Khan, M. Camps, J.W. Drijfhout, A.L. Silva, W. Jiskoot, T. van Hall, P.A. van Veelen, G. Janssen, K. Franken, L.J. Cruz, A. Tromp, J. Oostendorp, S.H. van der Burg, F. Ossendorp, and C.J. Melief Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation Eur. J. Immunol. 43 2013 2554 2565
20. M.W. Moore, F.R. Carbone, and M.J. Bevan Introduction of soluble protein into the class I pathway of antigen processing and presentation Cell 54 1988 777 785
21. A. Umar, B.K. Dunn, and P. Greenwald Future directions in cancer prevention Nat. Rev. Cancer 12 2012 835 848
22. L.J. Cruz, P.J. Tacken, R. Fokkink, B. Joosten, M.C. Stuart, F. Albericio, R. Torensma, and C.G. Figdor Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro J Control Release 144 2010 118 126
23. T.B. Geijtenbeek, and S.I. Gringhuis Signalling through C-type lectin receptors: shaping immune responses Nat. Rev. Immunol. 9 2009 465 479
24. R. Elgueta, M.J. Benson, V.C. de Vries, A. Wasiuk, Y. Guo, and R.J. Noelle Molecular mechanism and function of CD40/CD40L engagement in the immune system Immunol. Rev. 229 2009 152 172
25. C.G. Figdor, Y. van Kooyk, and G.J. Adema C-type lectin receptors on dendritic cells and Langerhans cells Nat. Rev. Immunol. 2 2002 77 84 (Pubitemid 37323231)
26. Z. Zhang, S. Tongchusak, Y. Mizukami, Y.J. Kang, T. Ioji, M. Touma, B. Reinhold, D.B. Keskin, E.L. Reinherz, and T. Sasada Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery Biomaterials 32 2011 3666 3678
27. V. Manolova, A. Flace, M. Bauer, K. Schwarz, P. Saudan, and M.F. Bachmann Nanoparticles target distinct dendritic cell populations according to their size Eur. J. Immunol. 38 2008 1404 1413
28. D. Raghuwanshi, V. Mishra, M.R. Suresh, and K. Kaur A simple approach for enhanced immune response using engineered dendritic cell targeted nanoparticles Vaccine 30 2012 7292 7299
29. P.J. Tacken, and C.G. Figdor Targeted antigen delivery and activation of dendritic cells in vivo: steps towards cost effective vaccines Semin. Immunol. 23 2011 12 20
30. S. Burgdorf, and C. Kurts Endocytosis mechanisms and the cell biology of antigen presentation Curr. Opin. Immunol. 20 2008 89 95
31. B. Chatterjee, A. Smed-Sorensen, L. Cohn, C. Chalouni, R. Vandlen, B.C. Lee, J. Widger, T. Keler, L. Delamarre, and I. Mellman Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells Blood 120 2012 2011 2020
32. F.V. Castro, A.L. Tutt, A.L. White, J.L. Teeling, S. James, R.R. French, and M.J. Glennie CD11c provides an effective immunotarget for the generation of both CD4 and CD8 T cell responses Eur. J. Immunol. 38 2008 2263 2273
33. J.P. Almeida, A.L. Chen, A. Foster, and R. Drezek In vivo biodistribution of nanoparticles Nanomedicine 6 2011 815 835
34. L.T. Sa, S. Albernaz Mde, B.F. Patricio, M.V. Falcao Jr., B.F. Coelho, A. Bordim, J.C. Almeida, and R. Santos-Oliveira Biodistribution of nanoparticles: initial considerations J. Pharm. Biomed. Anal. 70 2012 602 604
35. B. Semete, L. Booysen, Y. Lemmer, L. Kalombo, L. Katata, J. Verschoor, and H.S. Swai In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems Nanomedicine 6 2010 662 671